Jazz’s Commitment to Patients Highlighted During National Epilepsy Awareness Month

Ryan Bovia

National Epilepsy Awareness Month (NEAM) marks an important moment in time for epilepsy patients, their caregivers, family members and loved ones. During this year’s NEAM, my colleagues and I are hopeful that we can work to help “Remove the Filter” and not only address the challenges those with epilepsy may face, but also create awareness around a condition that impacts nearly one in 26 people in the United States.

Epilepsy, a neurological disorder which impacts approximately 3.4 million people nationwide, is one of the most common neurological conditions. Epilepsy can be characterized by the occurrence of at least two unprovoked seizures occurring more than 24 hours apart or by one unprovoked seizure with a high probability of further seizures. Here at Jazz, we’ve focused our efforts into exploring rare and severe forms of epilepsy.

At Jazz, we believe all people, particularly those who live with complex conditions, deserve new and better therapeutic options as there is still significant unmet patient need. Our research and development teams use their expertise to lead clinical programs across epilepsy and develop an industry-leading cannabinoid science platform that provides deeper understanding of the disease.

During NEAM, it’s important to remind ourselves of the role that we play in working for people in need, and how we can continue to advocate for patients and their caregivers. During NEAM, we’ll work to Remove the Filter – a way to highlight challenges those with epilepsy face, as well as continue to drive awareness for those with the disease. I am proud to be a part of a team who remains committed to fulfilling our responsibility to develop new medicines to treat rare, treatment-resistant epileptic conditions, and I am encouraged by our team’s dedication to create more innovative and improved options to transform the lives of patients and their families and Remove the Filter for all.